Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs D Wave Quantum Inc (QBTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs D Wave Quantum Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224 (market cap $29.60B), while D Wave Quantum Inc trades at $20.59 (market cap $7.53B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 3.9× D Wave Quantum Inc's market cap, and D Wave Quantum Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | QBTS | |
|---|---|---|
Market Cap | $29.60B | $7.53B |
Sector | Health | Technology |
52-Week High | $491.22 | $44.78 |
52-Week Low | $205.48 | $12.98 |
Enterprise Value | $27.56B | $7.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
D-Wave Quantum (QBTS) trades at $20.75, up 2.77% today, but faces bearish technical signals amid mixed earnings performance. The company reported a Q2 2026 loss of $0.10 per share, missing estimates, while revenue remained flat at $3.1 million. Despite negative profitability metrics, analyst consensus remains unanimously bullish with a $38.29 price target, reflecting optimism about quantum computing adoption and strong bookings growth.
The stock presents high-risk speculative potential with significant valuation concerns trading at 584x sales. While institutional interest and government funding support long-term quantum computing prospects, persistent losses and declining revenue create substantial execution risk. Investors must weigh Wall Street optimism against fundamental weaknesses in this emerging technology play.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About D Wave Quantum Inc
D-Wave Quantum Inc. is a global leader in the development and delivery of quantum computing systems, software, and services. The company specializes in annealing quantum computers designed to solve complex optimization problems across industries such as logistics, materials science, and financial modeling. D-Wave offers its technology through the cloud, allowing customers to build and run real-world quantum applications today, making it a key player in the commercialization of quantum computing.
Read more on QBTS →
